Japan Lifeline Co., Ltd., a prominent medical device company, has announced a corporate reorganization set to take effect on July 1, 2025. The company's Board of Directors resolved to abolish the Global OEM Initiative Office within the R&D and Production Group, along with the Production Control and Procurement Departments of the Supply Chain Division. Despite these changes, the functions of the Production Control and Procurement Departments will continue to be managed by the Supply Chain Division. This restructuring aims to streamline operations and enhance efficiency.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。